Synapse - Works

Results (2639)

Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL

Meeting Abstract

Zelenetz, A. D.; Brown, J. R.; Delgado, J.; Eradat, H.; Ghia, P.; Jacob, A.; Jurczak, W.; Loscertales, J.; MacDonald, D.; Morschhauser, F.; more...
Blood (2016)

Fulltext@MSK | Save

Molecular basis of ibrutinib resistance in Waldenstrom's macroglobulinemia

Meeting Abstract

Xu, L.; Tsakmaklis, N.; Yang, G.; Chen, J. G.; Liu, X.; Chen, J.; Demos, M.; Patterson, C. J.; Dubeau, T.; Meid, K.; more...
Blood (2016)

Fulltext@MSK | Save

AMC-053: Pilot study of an oncolytic viral strategy using bortezomib with ICE +/- rituximab for relapsed/refractory HIV+ lymphomas

Meeting Abstract

Reid, E. G.; Looney, D.; Maldarelli, F.; Noy, A.; Henry, D. H.; Aboulafia, D. M.; Ramos, J. C.; Sparano, J.; Ambinder, R. F.; Lee, J.; more...
Blood (2016)

Fulltext@MSK | Save

Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL

Meeting Abstract

Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
Blood (2016)

Fulltext@MSK | Save

Single-agent ibrutinib demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, phase 2 study

Meeting Abstract

Noy, A.; de Vos, S.; Thieblemont, C.; Martin, P.; Flowers, C.; Morschhauser, F.; Collins, G. P.; Ma, S.; Coleman, M.; Peles, S.; more...
Blood (2016)

Fulltext@MSK | Save

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma

Meeting Abstract

Mondello, P.; Derenzini, E.; Asgari, Z.; Philip, J.; Brea, E. J.; Seshan, V. E.; Hendrickson, R.; de Stanchina, E.; Scheinberg, D. A.; Younes, A.
Blood (2016)

Fulltext@MSK | Save

Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sezary syndrome: Clinical efficacy in a CITN multicenter phase 2 study

Meeting Abstract

Khodadoust, M.; Rook, A. H.; Porcu, P.; Foss, F. M.; Moskowitz, A. J.; Shustov, A. R.; Shanbhag, S.; Sokol, L.; Shine, R.; Fling, S. P.; more...
Blood (2016)

Fulltext@MSK | Save

Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (methotrexate or bexarotene): The phase 3 alcanza study

Meeting Abstract

Kim, Y. H.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Dummer, R.; Scarisbrick, J. J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Wang, Y.; more...
Blood (2016)

Fulltext@MSK | Save

MYC-dependent PI3K and MCL-1 feedbacks attenuate BET inhibitors activity in diffuse large B-cell lymphoma

Meeting Abstract

Derenzini, E.; Mondello, P.; Liu, Y.; Scallion, M.; Asgari, Z.; Philip, J.; Hilden, P.; Djaballah, H.; Ouerfelli, O.; de Stanchina, E.; more...
Blood (2016)

Fulltext@MSK | Save

The outcome of patients with primary refractory or relapsed peripheral T-cell lymphoma: Analysis of 1020 cases registered in the prospective T-cell project

Meeting Abstract

Bellei, M.; Foss, F. M.; Horwitz, S. M.; Marcheselli, L.; Kim, W. S.; Cabrera, M. E.; Dlouhy, I.; Nagler, A.; Advani, R. H.; Pesce, E.; more...
Blood (2016)

Fulltext@MSK | Save